Hunt­ing a T-cell cure for sol­id tu­mors, Rick Klaus­ner’s Lyell steers to Nas­daq — with big dreams and fresh for­tunes on the line

In the 3 years since ex-NCI chief Rick Klaus­ner found­ed Lyell, he’s raised hun­dreds of mil­lions of dol­lars, re­cruit­ed some of the top sci­en­tists in the field of cell ther­a­py 2.0 and al­lied him­self with an ar­ray of big and small ex­plor­ers in­volved in the quest of mas­ter­ing cell ex­haus­tion and dura­bil­i­ty.

Tues­day, though, was a time for throw­ing some dice on Nas­daq, and wait­ing to see how for­tunes could be divvied up in the IPO to come.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN